Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan

OBJECTIVE: Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in Japan. METHODS: Patients were followed...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugamori, Haruko, Lee, Takumi, Mitomi, Takeshi, Yamagishi, Chika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264337/
https://www.ncbi.nlm.nih.gov/pubmed/35523692
http://dx.doi.org/10.1093/jjco/hyac069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264337/
https://www.ncbi.nlm.nih.gov/pubmed/35523692
http://dx.doi.org/10.1093/jjco/hyac069

Ejemplares similares